About Kadmon Holdings
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: KDMN
- Previous Close: $3.59
- 50 Day Moving Average: $4.29
- 200 Day Moving Average: $6.21
- 52-Week Range: $3.49 - $11.73
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.47
- P/E Growth: 0.00
- Market Cap: $161.83M
- Outstanding Shares: 45,078,000
What is Kadmon Holdings' stock symbol?
Kadmon Holdings trades on the NASDAQ under the ticker symbol "KDMN."
Where is Kadmon Holdings' stock going? Where will Kadmon Holdings' stock price be in 2017?
5 analysts have issued 12-month price objectives for Kadmon Holdings' stock. Their forecasts range from $7.50 to $25.00. On average, they expect Kadmon Holdings' share price to reach $14.10 in the next twelve months.
When will Kadmon Holdings announce their earnings?
Kadmon Holdings is scheduled to release their next quarterly earnings announcement on Wednesday, November, 9th 2016.
What are analysts saying about Kadmon Holdings stock?
Here are some recent quotes from research analysts about Kadmon Holdings stock:
According to Zacks Investment Research, "Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. " (1/11/2017)
Citigroup Inc. analysts commented, "We believe investors could find a better de-risked entry point in the next 12–18 months with more data as we see long term upside," analyst Robyn Karnauskas wrote in a note.Related Link: "Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality," H.C. Wainwright Says"While we note 40–100 percent upside if every POC trial works, the stock could trade at $3–$5/sh (50–70 percent downside) if Tesevatinib fails in cancer trials & could trade at cash ($1/sh) if KD-025 also fails due to safety," the analyst continued.Karnauskas noted that the company may face cash crunch beyond first–second quarter of 2017 and they may be at risk of going to capital markets again before majority of data readout in the second half of 2017.That said, the analyst is positive on the Tesevatinib cancer program, as it crosses the blood brain barrier."We see FV of this program at $9/sh (75 percent of our valuation) and model 35 percent probability to brain met NSCLC opportunity ($400 million peak unadjusted) and 25 percent probability to GBM opportunity ($800 million peak unadjusted)," (8/22/2016)
Who owns Kadmon Holdings stock?
Kadmon Holdings' stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (4.90%), Anchorage Capital Group L.L.C. (0.28%), State Street Corp (0.16%) and Kingdon Capital Management L.L.C. (0.12%). Company insiders that own Kadmon Holdings stock include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov.
Who bought Kadmon Holdings stock? Who is buying Kadmon Holdings stock?
Kadmon Holdings' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC and State Street Corp. Company insiders that have bought Kadmon Holdings stock in the last two years include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov.
How do I buy Kadmon Holdings stock?
Shares of Kadmon Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Kadmon Holdings stock cost?
One share of Kadmon Holdings stock can currently be purchased for approximately $3.59.